Recent news on Rifaximin

Salix Pharmaceuticals Previews Digestive Disease Week 2007  -  May 17, 2007
Genetic Engineering News (press release),XIFAXAN(R) (rifaximin) tablets 200 mg are indicated for the treatment of patients (greater than or equal to 12 years of age) with travelers' diarrhea caused

New Ways to Ease IBS  -  Apr 26, 2007
WSIL TV,Working on the theory that bacteria may cause IBS, Dr. Pimentel, of Cedars-Sinai Medical Center in Los Angeles, tested the antibiotic rifaximin on 87 IBS

Salix Pharmaceuticals Previews Digestive Disease Week 2007  -  May 17, 2007
Business Wire (press release),The oral nonsystemic antibiotic rifaximin prevents symptom recurrence in patients with recurrent C. difficile-associated diarrhea

Antibiotic Could Make IBS Less Irritable  -  Apr 13, 2007
10News.com,Working on the theory that bacteria might cause IBS, Pimentel tested the antibiotic Rifaximin on 87 IBS patients. Nearly 40 percent of the patients saw a

Salix Pharmaceuticals Announces 1Q2007 Financial Results ...  -  Apr 24, 2007
PharmaLive.com (press release),Salix markets COLAZAL(R) (balsalazide) Capsules 750 mg, XIFAXAN(R) (rifaximin) Tablets, OSMOPREP(TM) (sodium phosphate monobasic monohydrate, USP,

Salix Pharmaceuticals Licenses DIACOL™ to Dr. Falk Pharma in Europe  -  Apr 17, 2007
Business Wire (press release),Salix markets COLAZAL ® (balsalazide) Capsules, XIFAXAN ® (rifaximin) Tablets, OSMOPREP™ (sodium phosphate monobasic monohydrate, USP, and sodium phosphate

Leading Experts Call for Immediate Improvements to Control Global ...  -  Apr 3, 2007
Infection Control Today,Among the promising therapies under evaluation are gastrointestinal flora-sparing antibiotics, Difimicin and Rifaximin, and a toxin binder, Tolevamer.

Salix Pharmaceuticals Reports 4Q2006 and FY2006 Results  -  Feb 28, 2007
Genetic Engineering News (press release),XIFAXAN(R) (rifaximin) tablets 200 mg are indicated for the treatment of patients (Greater Than or Equal to 12 years of age) with travelers' diarrhea caused

Salix Pharmaceuticals Reports 4Q2006 and FY2006 Results  -  Feb 28, 2007
Business Wire (press release),XIFAXAN ® (rifaximin) tablets 200 mg are indicated for the treatment of patients (≥12 years of age) with travelers' diarrhea caused by noninvasive strains

New Way to Ease IBS  -  Feb 19, 2007
WQAD,Working on the theory that bacteria may cause IBS, Dr. Pimentel, of Cedars-Sinai Medical Center in Los Angeles, tested the antibiotic rifaximin on 87 IBS

Locating the Source of Irritable Bowel Syndrome  -  Feb 14, 2007
WNDU-TV,Working the theory that bacteria may cause IBS, Carol was put on the antibiotic, rifaximin. On 87 patients, nearly 40% saw a major improvement in symptoms.

Bacteria May Be Cause Of IBS  -  Jan 31, 2007
TheDenverChannel.com,Pimentel tested the antibiotic Rifaximin on 87 IBS patients and found that nearly 40 percent saw a major improvement in symptoms.

Antibiotic Officer Promise In Treating IBS  -  Jan 15, 2007
News4Jax.com,Researchers at Cedars-Sinai Medical Center, Los Angeles conducted a study to determine if a non-absorbed antibiotic, rifaximin, is more effective than a

New Way to Ease IBS  -  Jan 15, 2007
ABC7Chicago.com,ANTIBIOTIC TREATMENT: Rifaximin is an antibiotic treatment for IBS that works on the theory bacteria causes some bowel problems.

Doctor finds new way to treat IBS  -  Jan 8, 2007
KING5.com (subscription),Working on the theory that bacteria may cause IBS, Dr. Pimentel tested the antibiotic rifaximin on 87 patients. Nearly 40 percent saw major improvement.

Suffering From Chronic Constipation?  -  Nov 27, 2006
Science Daily (press release)Reduce Bloating And Excess Gas With A Common Antibiotic (February 15, 2006) -- In the first study of its kind, researchers discovered that rifaximin,

Debiopharm and Salix Pharmaceuticals sign license agreement for ...  Sep 5, 2006
Salix markets Colazal(R) (balsalazide disodium) Capsules 750 mg, Xifaxan(R) (rifaximin) tablets 200 mg, Visicol(R) Tablets (sodium phosphate monobasic ... -Canada NewsWire

Salix Pharmaceuticals and Debiopharm Sign SANVAR(R) License ...  Sep 6, 2006
Salix markets Colazal® (balsalazide disodium) Capsules 750 mg, Xifaxan® (rifaximin) tablets 200 mg, Visicol® Tablets (sodium phosphate monobasic monohydrate ... -PipelineReview.com

Dr. Mark Pimentel's Protocol Being Featured in Parade Magazine  -  Nov 17, 2006
Genetic Engineering News (press release),GI Motility Program at Cedars-Sinai Medical Center, patients suffering from IBS should consider taking Rifaximin for treating Irritable Bowel Syndrome.

Suffering From Chronic Constipation?  -  Nov 27, 2006
Science Daily (press release)Reduce Bloating And Excess Gas With A Common Antibiotic (February 15, 2006) -- In the first study of its kind, researchers discovered that rifaximin,

New Treatment Available For IBS  Aug 23, 2006
..."The most effective antibiotic we found is Rifaximin, 70 percent likely hood of getting rid of the bacteria and you take it for 10 days," says Dr. Pimental. ... -CBS 3

Salix Pharmaceuticals Reports 2Q2006 Results  Aug 8, 2006
XIFAXAN(R) (rifaximin) tablets 200 mg are indicated for the treatment of patients (greater than or equal to 12 years of age) with travelers' diarrhea caused by ... -Business Wire

MoviPrep(R) Granted FDA Marketing Approval; New Two-Liter Liquid ...  Aug 2, 2006
Salix also markets Colazal(R) (balsalazide disodium) Capsules 750 mg, Xifaxan(R) (rifaximin) tablets 200 mg, Visicol(R) Tablets (sodium phosphate monobasic ... -Genetic Engineering News

MOVIPREP(R) Granted FDA Marketing Approval  Aug 3, 2006
Salix also markets Colazal® (balsalazide disodium) Capsules 750 mg, Xifaxan® (rifaximin) tablets 200 mg, Visicol® Tablets (sodium phosphate monobasic ... -PipelineReview.com

Salix Pharmaceuticals In Arrangement With Cedars-Sinai Medical ...  Jul 5, 2006
...provides Salix exclusive worldwide license to make, have made, use, sell and have sold and import licensed products related to the use of rifaximin, which is ... -Trading Markets

Salix Expands XIFAXAN(R) Intellectual Property; Secures License ...  Jul 5, 2006
...grants Salix an exclusive worldwide license to make, have made, use, sell and have sold and import licensed products related to the use of rifaximin, which we ... -Genetic Engineering News

Salix Licenses Wider Use For Use Of Patents Used In Bowel Drug  Jul 6, 2006
...bowel syndrome. Salix now has worldwide rights to market and sell licensed products related to rifaximin on a global basis. Salix ... -Local Tech Wire



Salix Pharmaceuticals Reports 1Q2006 Results  May 4, 2006
XIFAXAN(R) (rifaximin) tablets 200 mg are indicated for the treatment of patients (greater than or equal to 12 years of age) with travelers' diarrhea caused by ... - Genetic Engineering News

Salix Announces Completion of OsmoPrep(TM) versus Liquid Bowel ...  Apr 19, 2006
Salix also markets COLAZAL(R) (balsalazide disodium) Capsules 750 mg, XIFAXAN(R) (rifaximin) tablets 200 mg, VISICOL(R) Tablets (sodium phosphate monobasic ... - Genetic Engineering News





Update on major health topics: Back pain, intestinal gas  Mar 12, 2006
STUDY randomly assigned 124 adults with frequent symptoms related to intestinal gas, including bloating and flatulence, to take the antibiotic rifaximin or a ... - Seattle Times

OsmoPrep(TM) Tablets Granted FDA Marketing Approval; New Tablet ...  Mar 17, 2006
Salix also markets COLAZAL(R) (balsalazide disodium) Capsules 750mg, XIFAXAN(R) (rifaximin) tablets 200 mg, VISICOL(R) Tablets (sodiumphosphate monobasic ... - Finanzen.net



An antibiotic that can rid you of your flatulence  Feb 18, 2006
In the first study of its kind, researchers discovered that an antibiotic used to treat diarrhoea,rifaximin, is an effective treatment for abdominal bloating ... - Webindia123,

Novel Treatment For Irritable Bowel Syndrome Patients  Feb 15, 2006
Lebanon (AHN) - Researchers discovered that rifaximin, an antibiotic used to treat diarrhea, is also effective in treating abdominal bloating and flatulence ... - All Headline News

Salix Pharmaceuticals Reports 4Q2005 and FY2005 Results; 2005 ...  Feb 24, 2006
XIFAXAN(R) (rifaximin) tablets 200 mg are indicated for the treatment of patients (greater than or equal to12 years of age) with travelers' diarrhea caused by ... - Genetic Engineering News,

Salix Pharmaceuticals Development Update; XIFAXAN(R) Trials ...  Jan 11, 2006
XIFAXAN (rifaximin), dosed 400 mg three times daily, is being investigated in a vancomycin comparator, 300-subject Phase III trial to evaluate the efficacy and ... - Business Wire

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional